Larotrectinib (Lar) is a highly selective and potent small‐molecule inhibitor of all three tropomyosin receptor kinase (TRK) proteins, TRKA, TRKB and TRKC, in patients with TRK fusion‐positive cancer, including colon cancer.9 The gene discussed is NTRK1; the disease is cancer.